Fig. 3
From: Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
CD5-IL15/IL15sushi CAR T cells display potent lysis of malignant CD5 + lymphoblasts in CSF. a Prior to CD5-IL15/IL15sushi CAR T cell therapy, CSF analysis demonstrated a substantial increase in lymphoblasts, accounting for around 80% of the CSF cells, that were almost 100% CD5 + C34+ (circled population). b One week following CAR infusion, the lymphoblasts decreased dramatically, now accounting for only about 2% of the patient’s CSF cells. c Two weeks following therapy, the percentage had decreased to just under 2%, d three weeks after therapy it had decreased to just under 1%, e and by four weeks post-CAR, lymphoblasts were undetectable in the CSF. f Graphical summary of the CSF lymphoblast population in the weeks after CAR therapy